Polar Capital Holdings Plc lessened its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 90.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 65,500 shares of the company's stock after selling 589,500 shares during the quarter. Polar Capital Holdings Plc owned 0.08% of IDEAYA Biosciences worth $1,683,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the business. R Squared Ltd purchased a new position in IDEAYA Biosciences during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. raised its position in IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after acquiring an additional 853 shares in the last quarter. KBC Group NV raised its position in IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after acquiring an additional 1,923 shares in the last quarter. Cibc World Markets Corp purchased a new position in IDEAYA Biosciences during the fourth quarter valued at approximately $203,000. Finally, Mariner LLC raised its position in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock valued at $251,000 after acquiring an additional 869 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently commented on IDYA shares. JPMorgan Chase & Co. boosted their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research report on Thursday. Stephens restated an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $54.27.
Read Our Latest Stock Report on IDYA
IDEAYA Biosciences Stock Performance
Shares of NASDAQ:IDYA traded down $0.09 during trading on Thursday, reaching $19.07. The stock had a trading volume of 328,170 shares, compared to its average volume of 1,003,630. The business has a fifty day moving average price of $17.66 and a 200-day moving average price of $22.07. The stock has a market cap of $1.67 billion, a PE ratio of -5.78 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the business earned ($0.53) earnings per share. Sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.
IDEAYA Biosciences Company Profile
(
Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Further Reading
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
